Across TCGA pan-cancer cohorts, C2orf76 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C2orf76 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher C2orf76 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated C2orf76 expression acts as an unfavorable survival marker.

CESC, BLCA, and SKCM are the cancer types where C2orf76 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.068	0.875	<.001	36	view →
BLCA	DFS	Median	All	0.240	0.627	.042	12	view →
SKCM	OS	Median	All	0.193	0.781	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C2orf76 tumor-vs-normal RNA expression · all C2orf76 data types